

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067926 A1

(51) International Patent Classification⁷: **A61K 31/4422**,
A61P 9/00, A61K 9/14

(21) International Application Number:
PCT/KR2005/000120

(22) International Filing Date: 14 January 2005 (14.01.2005)

(25) Filing Language: Korean

(26) Publication Language: English

(30) Priority Data:
10-2004-0003439 16 January 2004 (16.01.2004) KR

(71) Applicant (for all designated States except US): **CHONG KUN DANG PHARMACEUTICAL CORP.** [KR/KR];
368 Choongjungro-3ka, Sudaemoon-ku, C.P.O. Box 3477,
Seoul 120-756 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **LEE, Sang-Joon** [KR/KR]; 939-503 Mohyang Apt., Sanbon 1148,
Gunpo-si, Gyeonggi-do 435-040 (KR). **SHIN, Hee-Jong** [KR/KR]; 1404-101, Yeonhwamaeul., #14-1, Jung2-dong,
Wonmi-gu, Bucheon-si, Gyeonggi-do 420-022 (KR). **LIM, Jong-Lae** [KR/KR]; 102-738 Dongbo Apt., #253-38,
Mosi-ri, Jiksan-myeon, Cheonan-si, Chungcheongnam-do 330-814 (KR). **LEE, Seok-Kyu** [KR/KR]; 105-901,
Hanladongbaek2cha Apt., 909 Sinbang-dong, Cheonan-si, Chungcheongnam-do 330-768 (KR). **MOON, Soo-Yeon** [KR/KR]; 307 Hongikofficetel, Sunghwang-dong, Cheo-
nan-si, Chungcheongnam-do 330-130 (KR). **PARK, Shin-Jung** [KR/KR]; 101-420 Joyangimdae Apt.,

252 Jeo-ri, Sunggeo-eub, Cheonan-si, Chungcheong-
nam-do 330-836 (KR). **SHIN, Taek-Hwan** [KR/KR];
104-102 Samil Apt., Jeo-ri, Sunggeo-eub, Cheonan-si,
Chungcheongnam-do 330-836 (KR).

(74) Agent: **ROH, Jae-Chull**; WAY with ROH Patent & Law
Office, 4F., Halla Building, #641-17, Yeoksam-dong,
Gangnam-gu, Seoul, 135-909 (KR).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG,
MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO,
SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITION OF AMLODIPINE MALEATE HAVING ENHANCED STABILITY

(57) Abstract: The present invention relates to a coated particle of amlodipine maleate and a pharmaceutical composition for car-
diovascular disease (CVD) comprising the coated particle of amlodipine maleate. The pharmaceutical composition of the present
invention has stable bioavailability due to sufficient dissolution rate and prevents decomposition reaction of amlodipine to thereby
being formulated with formulation-stability equal to or higher than amlodipine besylate under long storage.

WO 2005/067926 A1